Serum brain-derived neurotrophic factor levels as a novel biological marker for the activities of psychiatric symptoms in systemic lupus erythematosus

World Journal of Biological Psychiatry

Volumn 11, Issue 2, 2010, Pages 121-128

  Ikenouchi Sugita, Atsuko ^a   Yoshimura, Reiji ^a   Okamoto, Tatsuya ^a   Umene Nakano, Wakako ^a   Ueda, Nobuhisa ^a   Hori, Hikaru ^a   Katsuki, Asuka ^a   Saito, Kazuyoshi ^a   Tanaka, Yoshiya ^a   Nakamura, Jun ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Acute confusion state; Biological marker; Brain derived neurotrophic factor; Mood disorder; Neuropsychiatric systemic lupus erythematosus; Organic brain syndrome

Indexed keywords

BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; IMMUNOGLOBULIN G; INTERLEUKIN 6;

ACUTE CONFUSION; ADULT; ANXIETY DISORDER; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MOOD DISORDER; ORGANIC BRAIN SYNDROME; PSYCHOSIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOGLOBULIN G; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS VASCULITIS, CENTRAL NERVOUS SYSTEM; MALE; MENTAL DISORDERS; MIDDLE AGED; YOUNG ADULT;

EID: 77649139803     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.3109/15622970903521131     Document Type: Article

References (50)

1. Alcocer-Varela J, Aleman-Hoey D, Alarcon-Segovia D. 1992. Interleukin-1 and interleukin-6 activities are increased in the cerebrospinal fluid of patients with CNS lupus erythematosus and correlate with local late T-cell activation markers. Lupus 1:111-117
2. American College of Rheumatology. 1999. The American College of Rheumatology nomenclature and case defi nitions for neuropsychiatric lupus syndromes. Arthritis Rheum 42: 599-608.
3. Abdel-Nasser AM, Ghaleb RM, Mahmoud JA, Khairy W, Mahmoud RM. 2008. Association of anti-ribosomal P protein antibodies with neuropsychiatric and other manifestations of systemic lupus erythematosus. Clin Rheumatol 27:1377-1385.
4. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. 1992. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 35:630-640.
5. Chiaretti A, Antonelli A, Piastra M, Genovese O, Polidori G, Aloe L. 2004. Expression of neurotrophic factors in cerebros-pinal fluid and plasma of children with viral and bacterial meningoencephalitis. Acta Paediatr 93:1178-1184.
6. del Porto F, Aloe L, Lagana B, Triaca V, Nofroni I, D'Amelio R. 2006. Nerve growth factor and brain-derived neurotrophic factor levels in patients with rheumatoid arthritis treated with TNF-alpha blockers. Ann NY Acad Sci 1069:438-443.
7. Fauchais AL, Boumediene A, Lalloue F, Gondran G, Loustaud-Ratti V, Vidal E, et al. 2009. Brain-derived neurotrophic factor and nerve growth factor correlate with T-cell activation in primary Sjogren's syndrome. Scand J Rheumatol 38:50-57.
8. Gold SM, Schulz KH, Hartmann S, Mladek M, Lang UE, Hellweg R, et al. 2003. Basal serum levels and reactivity of nerve growth factor and brain-derived neurotrophic factor to standardized acute exercise in multiple sclerosis and controls. J Neuroimmunol 138:99-105.
9. Hall RC, Popkin MK, Stickney SK, Gardner ER. 1979. Presentation of the steroid psychoses. J Nerv Ment Dis 167:229-236.
10. Hashimoto K, Iwata Y, Nakamura K, Tsujii M, Tsuchiya KJ, Sekine Y, et al. 2006. Reduced serum levels of brain-derived neurotrophic factor in adult male patients with autism. Prog Neuropsychopharmacol Biol Psychiatry 30:1529-1531.
11. Hirohata S, Tanimoto K, Ito K. 1993. Elevation of cerebrospinal fluid interleukin-6 activities in patients with vasculitides and central nervous system involvement. Clin Immunol Immun-opathol 66:225-229.
12. Hochberg MC. 1997. Updating the American College of Rheumatology revised criteria for the classifi cation of systemic lupus erythematosus. Arthritis Rheum 40:1725.
13. Hori H, Yoshimura R, Yamada Y, Ikenouchi A, Mitoma M, Ida Y, et al. 2007. Effects of olanzapine on plasma levels of catecholamine metabolites, cytokines, and brain-derived neurotrophic factor in schizophrenic patients. Int Clin Psychopharmacol 22:21-27.
14. Ikeda Y, Yahata N, Ito I, Nagano M, Toyota T, Yoshikawa T, et al. 2008. Low serum levels of brain-derived neurotrophic factor and epidermal growth factor in patients with chronic schizophrenia. Schizophr Res 101:58-66.
15. Ikenouchi A, Yoshimura R, Ikemura N, Utsunomiya K, Mitoma M, Nakamura J. 2006. Plasma levels of brain derived-neurotrophic factor and catecholamine metabolites are increased during active phase of psychotic symptoms in CNS lupus: a case report. Prog Neuropsychopharmacol Biol Psychiatry 30: 1359-1363.
16. Jacobsen JP, Mork A. 2006. Chronic corticosterone decreases brain-derived neurotrophic factor (BDNF) mRNA and protein in the hippocampus, but not in the frontal cortex, of the rat. Brain Res 1110:221-225.
17. Karassa FB, Magliano M, Isenberg DA. 2003. Suicide attempts in patients with systemic lupus erythematosus. Ann Rheum Dis 62:58-60.
18. Karege F, Schwald M, Cisse M. 2002. Postnatal developmental profi le of brain-derived neurotrophic factor in rat brain and platelets. Neurosci Lett 328:261-264
19. Karege F, Bondolfi G, Gervasoni N, Schwald M, Aubry JM, Bertschy G. 2005. Low brain-derived neurotrophic factor (BDNF) levels in serum of depressed patients probably results from lowered platelet BDNF release unrelated to platelet reactivity. Biol Psychiatry 57:1068-1072.
20. Laske C, Stransky E, Eschweiler, GW, Klein R, Wittorf A, Leyhe T, et al. 2007. Increased BDNF serum concentration in fi bromyalgia with or without depression or antidepressants. J Psychiatr Res 41:600-605.
21. Lewin GR, Barde YA. 1996. Physiology of the neurotrophins. Annu Rev Neurosci 19:289-317.
22. Lewis DA, Smith RE. 1983. Steroid-induced psychiatric syndromes. A report of 14 cases and a review of the literature. J Affect Disord 5:319-332.
23. Lommatzsch M, Zinger D, Schuhbaeck K, Schloetcke K, Zinger C, Schuff-Werner P, et al. 2005. The impact of age, weight and gender on BDNF levels in human platelets and plasma. Neu-robiology 26:115-123.
24. Machado-Vieira R, Dietrich MO, Leke R, Cereser VH, Zanatto V, Kapczinski F, et al. 2007. Decreased plasma brain derived neu-rotrophic factor levels in unmedicated bipolar patients during manic episode. Biol Psychiatry 61:142-144.
25. Monov S, Monova D. 2008. Classifi cation criteria for neuropsy-chiatric systemic lupus erythematosus: Do they need a discussion? Hippokratia 12:103-107.
26. Mossner R, Mikova O, Koutsilieri E, Saoud, M, Ehlis AC, Muller N, et al. 2007. Consensus paper of the WFSBP Task Force on Biological Markers: biological markers in depression. World J Biol Psychiatry 8:141-174.
27. Nakazato M, Hashimoto K, Shimizu E, Kumakiri C, Koizumi H, Okamura N, et al. 2003. Decreased levels of serum brain-derived neurotrophic factor in female patients with eating disorders. Biol Psychiatry 54:485-490. (Pubitemid 37289455)
28. Nockher WA, Renz H. 2003. Neurotrophins in inflammatory lung diseases: modulators of cell differentiation and neuroimmune interactions. Cytokine Growth Factor Rev 14:559-578.
29. Okamoto T, Yoshimura R, Ikenouchi-Sugita A, Hori H, Umene-Nakano W, Inoue Y, et al. 2008. Effi cacy of electroconvulsive therapy is associated with changing blood levels of homovanil-lic acid and brain-derived neurotrophic factor (BDNF) in refractory depressed patients: a pilot study. Prog Neuropsy-chopharmacol Biol Psychiatry 32:1185-1190.
30. Onen Sertoz O, Tolga Binbay I, Koylu E, Noyan A, Yildirim E, Elbi Mete H. 2008. The role of BDNF and HPA axis in the neurobiology of burnout syndrome. Prog Neuropsychophar-macol Biol Psychiatry 32:1459-1465.
31. Post RM. 2007. Role of BDNF in bipolar and unipolar disorder: clinical and theoretical implications. J Psychiatr Res 41:979-990.
32. Raap U, Goltz C, Deneka N, Bruder M, Renz H, Kapp A, et al. 2005. Brain-derived neurotrophic factor is increased in atopic dermatitis and modulates eosinophil functions compared with that seen in nonatopic subjects. J Allergy Clin Immunol 115:1268-1275.
33. Rage F, Silhol M, Tapia-Arancibia L. 2006. IL-1beta regulation of BDNF expression in rat cultured hypothalamic neurons depends on the presence of glial cells. Neurochem Int 49:433-441.
34. Rhoades HM, Overall JE. 1988. The semistructured BPRS interview and rating guide. Psychopharmacol Bull 24:101-104.
35. Rizos EN, Papadopoulou A, Laskos E, Michalopoulou PG, Kastania A, Vasilopoulos D, et al. 2008. Reduced serum BDNF levels in patients with chronic schizophrenic disorder in relapse, who were treated with typical or atypical antipsychotics. World J Biol Psychiatry 2008 Jul 10:1-5 (Epub ahead of print).
36. Schaaf MJ, De Kloet, ER and Vreugdenhil E. 2000. Corticoster-one effects on BDNF expression in the hippocampus. Implications for memory formation. Stress 3:201-208.
37. Schuhmann B, Dietrich A, Sel S, Hahn C, Klingenspor M, Lommatzsch, et al. 2005. A role for brain-derived neurotrophic factor in B cell development. J Neuroimmunol 163:15-23.
38. Schulte-Herbruggen O, Nassenstein C, Lommatzsch M, Quarcoo D, Renz H, Braun A. 2005. Tumor necrosis factor-alpha and interleukin-6 regulate secretion of brain-derived neurotrophic factor in human monocytes. J Neuroimmunol 160:204-209.
39. Sen, S, Duman R, Sanacora G. 2008. Serum brain-derived neu-rotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry 64:527-532.
40. Shimizu E, Hashimoto K, Okamura N, Koike K, Komatsu N, Kumakiri C, et al. 2003. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry 54: 70-75 (Pubitemid 36776725)
41. Shlomchik MJ, Madaio MP, Ni D, Trounstein M, Huszar D. 1994. The role of B cells in lpr/lpr-induced autoimmunity. J Exp Med 180:1295-1306.
42. Trysberg E, Carlsten H, Tarkowski A. 2000. Intrathecal cytokines in systemic lupus erythematosus with central nervous system involvement. Lupus 9:498-503.
43. Umene-Nakano W, Yoshimura R, Ikenouchi-Sugita A, Hori H, Hayashi K, Ueda N, et al. 2009. Serum levels of brain-derived neurotrophic factor in comorbidity of depression and alcohol dependence. Hum Psychopharmacol 24:409-413.
44. Vega JA, Garcia-Suarez O, Hannestad J, Perez-Perez M, Germana A. 2003. Neurotrophins and the immune system. J Anat 203: 1-19.
45. West SG. 1994. Neuropsychiatric lupus. Rheum Dis Clin North Am 20:129-158.
46. Yasutake C, Kuroda K, Yanagawa T, Okamura T, and Yoneda H. 2006. Serum BDNF, TNF-alpha and IL-1beta levels in dementia patients: comparison between Alzheimer's disease and vascular dementia. Eur Arch Psychiatry Clin Neurosci 256: 402-406.
47. Yoshimura R, Hori H, Sugita A, Ueda N, Kakihara S, Umene W, et al. 2007a. Treatment with risperidone for 4 weeks increased plasma 3-methoxy-4- hydroxypnenylglycol (MHPG) levels, but did not alter plasma brain-derived neurotrophic factor (BDNF) levels in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 31:1072-1077.
48. Yoshimura R, Mitoma M, Sugita A, Hori H, Okamoto T, Umene W, et al. 2007b. Effects of paroxetine or milnacipran on serum brain-derived neurotrophic factor in depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 31:1034-1037.
49. Yoshimura R, Ueda N, Hori H, Ikenouchi-Sugita A, Umene-Nakano W, Nakamura J.2008. Different patterns of longitudinal changes in plasma levels of catecholamine metabolites and brain-derived neurotrophic factor after administration of atypical antipsychotics in fi rst episode untreated schizophrenic patients. World J Biol Psychiatry Sep 2:1-6 (Epub ahead of print).
50. Yukimasa T, Yoshimura R, Tamagawa A, Uozumi T, Shinkai K, Ueda N, et al. 2006. High-frequency repetitive transcranial magnetic stimulation improves refractory depression by influencing catecholamine and brain-derived neurotrophic factors. Pharmacopsychiatry 39:52-59.